Figure 5
In vitro binding assays: (A) ELISA showing binding of [125I]VEGF (•), VEGF115-CPG2(Q)3-H6 (▵), VEGF161-CPG2(Q)3-H6 (□),or CPG2(Q)3-VEGF109-H6 (⋄) to VEGFR2(ΔKD)m. (B) RIA showing competition of CPG2(Q)3-H6 (○), VEGF115-CPG2(Q)3-H6 (▵), VEGF161-CPG2(Q)3-H6 (□), CPG2(Q)3-VEGF109-H6 (⋄), or VEGF165 (•) with [125I]VEGF for VEGFR2(ΔKD)m. (C) Kinetics of binding of VEGF115-CPG2(Q)3-H6 (▵),VEGF161-CPG2(Q)3-H6 (□),or CPG2(Q)3-VEGF109-H6 (⋄) to VEGFR2(ΔKD)m captured by immobilised 9E10 monoclonal antibody, measured by ELISA.
